LTC2205635I2 - - Google Patents

Info

Publication number
LTC2205635I2
LTC2205635I2 LTPA2022016C LTPA2022016C LTC2205635I2 LT C2205635 I2 LTC2205635 I2 LT C2205635I2 LT PA2022016 C LTPA2022016 C LT PA2022016C LT PA2022016 C LTPA2022016 C LT PA2022016C LT C2205635 I2 LTC2205635 I2 LT C2205635I2
Authority
LT
Lithuania
Application number
LTPA2022016C
Other languages
Lithuanian (lt)
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40242598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2205635(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of LTPA2022016I1 publication Critical patent/LTPA2022016I1/lt
Publication of LTC2205635I2 publication Critical patent/LTC2205635I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTPA2022016C 2007-09-10 2022-12-12 LTC2205635I2 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97117807P 2007-09-10 2007-09-10
US9167608P 2008-08-25 2008-08-25
PCT/US2008/010510 WO2009035577A1 (en) 2007-09-10 2008-09-09 Antigen binding proteins capable of binding thymic stromal lymphopoietin

Publications (2)

Publication Number Publication Date
LTPA2022016I1 LTPA2022016I1 (enExample) 2023-01-10
LTC2205635I2 true LTC2205635I2 (enExample) 2025-10-27

Family

ID=40242598

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP08830362.3T LT2205635T (lt) 2007-09-10 2008-09-09 Antigenus rišantys baltymai, gebantys prisijungti užkrūčio stromos limfopoetiną
LTPA2022016C LTC2205635I2 (enExample) 2007-09-10 2022-12-12

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP08830362.3T LT2205635T (lt) 2007-09-10 2008-09-09 Antigenus rišantys baltymai, gebantys prisijungti užkrūčio stromos limfopoetiną

Country Status (36)

Country Link
US (6) US7982016B2 (enExample)
EP (3) EP3524622A1 (enExample)
JP (9) JP5956716B2 (enExample)
KR (2) KR101597371B1 (enExample)
CN (2) CN104231081B (enExample)
AR (1) AR068508A1 (enExample)
AU (1) AU2008300028B2 (enExample)
CA (1) CA2698382C (enExample)
CL (2) CL2008002668A1 (enExample)
CR (2) CR11319A (enExample)
CY (2) CY1117702T1 (enExample)
DK (1) DK2205635T3 (enExample)
EA (2) EA201590631A1 (enExample)
ES (1) ES2581229T3 (enExample)
FR (1) FR22C1059I2 (enExample)
HR (1) HRP20160638T1 (enExample)
HU (2) HUE028361T2 (enExample)
IL (3) IL204069A (enExample)
JO (1) JO3351B1 (enExample)
LT (2) LT2205635T (enExample)
LU (1) LUC00289I2 (enExample)
MX (1) MX2010002590A (enExample)
MY (1) MY150242A (enExample)
NL (1) NL301207I2 (enExample)
NO (1) NO2022055I1 (enExample)
NZ (1) NZ583933A (enExample)
PE (2) PE20140232A1 (enExample)
PH (1) PH12017501025B1 (enExample)
PL (1) PL2205635T3 (enExample)
PT (1) PT2205635T (enExample)
RS (1) RS54950B1 (enExample)
SG (2) SG178781A1 (enExample)
SI (1) SI2205635T1 (enExample)
TW (2) TWI449709B (enExample)
WO (1) WO2009035577A1 (enExample)
ZA (1) ZA201001895B (enExample)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
EP2803675A3 (en) 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use
EP3594356A1 (en) * 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
CA2885176C (en) * 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2773774A4 (en) * 2011-11-03 2015-06-10 Merck Sharp & Dohme BIOMARKERS FOR TSLP TREATMENT
CN104507968B (zh) * 2012-04-27 2019-02-05 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
US20170103186A1 (en) 2014-06-03 2017-04-13 Amgen Inc. Systems and methods for supporting patient use of a drug delivery device
ES3056224T3 (en) 2014-10-14 2026-02-19 Amgen Inc Drug injection device with visual and audible indicators
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
EP3297672B1 (en) * 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EA038332B1 (ru) * 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
GB201615588D0 (en) * 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11001624B2 (en) * 2016-04-05 2021-05-11 Vib Vzw TSLP inhibitors
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
ES3066292T3 (en) 2016-06-03 2026-05-12 Amgen Inc Impact testing apparatuses and methods for drug delivery devices
EA201892716A1 (ru) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
RU2721582C1 (ru) * 2016-08-05 2020-05-20 И-Байолоджикс Инк. Антитела против лиганда-1 запрограммированной смерти (PD-L1) и их применение
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127B1 (en) 2016-10-25 2026-04-08 Amgen Inc. On-body injector
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
CA3045376C (en) * 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
MX2019011416A (es) 2017-03-28 2019-11-01 Amgen Inc Sistema y metodo para conjunto de jeringa y vastago de embolo.
EP3609917A1 (en) 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
US12103979B2 (en) 2017-04-28 2024-10-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
CN109206514B (zh) * 2017-07-03 2019-10-08 拜西欧斯（北京）生物技术有限公司 Tslp单克隆抗体及其制备方法和应用
JP7408398B2 (ja) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド 二重ねじりばねシステムを有する針挿入後退システム
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
BR112020001922A2 (pt) 2017-08-01 2020-08-04 Amgen Inc. sistemas e métodos para realização de um ensaio de glicanas em tempo real de uma amostra
EA202090399A1 (ru) 2017-08-01 2020-05-20 Эмджен Инк. Системы и способы для подготовки в режиме реального времени образца полипептида для анализа с помощью масс-спектрометрии
US12318593B2 (en) 2017-08-09 2025-06-03 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3669004A1 (en) 2017-08-16 2020-06-24 Medimmune, LLC Compositions and methods for treatment of atopic dermatitis and treatment selection
EP3668567B1 (en) 2017-08-18 2026-02-18 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
ES3069718T3 (en) 2017-11-03 2026-06-10 Amgen Inc System and approaches for sterilizing a drug delivery device
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
WO2019178280A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Sequential digestion of polypeptides for mass spectrometric analysis
WO2019178151A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
CN112469454B (zh) 2018-07-24 2024-01-26 安进公司 用于施用药物的输送装置
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
US12042642B2 (en) 2018-09-28 2024-07-23 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
JP7719714B2 (ja) 2018-10-15 2025-08-06 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
MA53913A (fr) 2018-10-15 2022-01-19 Amgen Inc Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US12000775B2 (en) 2018-12-14 2024-06-04 Amgen Inc. System suitability method for use with protein concentration determination by slope
US11452738B2 (en) 2019-01-04 2022-09-27 Empirico Inc. Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
CA3128233A1 (en) 2019-02-14 2020-08-20 Amgen Inc. Systems and methods for preparing a sample and performing a real-time assay of the sample
JP7530376B2 (ja) 2019-02-20 2024-08-07 アムジエン・インコーポレーテツド タンパク質の安定性を決定する方法
JP7570341B2 (ja) 2019-03-04 2024-10-21 アムジエン・インコーポレーテツド 高分子量種のインビボでの可逆性
US12078701B2 (en) 2019-03-27 2024-09-03 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
EP3958934B1 (en) 2019-04-24 2025-04-09 Amgen Inc. Syringe sterilization verification assemblies and methods
TWI917325B (zh) * 2019-06-04 2026-03-11 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
EP4517327A3 (en) 2019-06-05 2025-05-07 Amgen Inc. Methods of identifying attributes of therapeutic proteins
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合ｔｓｌｐ及びその使用
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
EP4045515A4 (en) 2019-10-18 2023-10-18 The Regents Of The University Of Michigan BIOMATERIAL SENSOR SYSTEMS
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
CN114887053B (zh) * 2019-11-29 2026-04-24 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
EP4047019A4 (en) * 2019-12-13 2023-11-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
EP4103605A1 (en) 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
CR20220457A (es) 2020-02-13 2023-01-09 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
MX2022010120A (es) 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN111662379B (zh) * 2020-05-09 2021-03-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) 抗新型冠状病毒的抗体、制备方法和应用
CN116829177A (zh) * 2020-05-20 2023-09-29 纽约市哥伦比亚大学理事会 抗SARS-CoV-2的有效中和抗体及其生成和用途
CA3184184A1 (en) * 2020-05-20 2021-11-25 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
JP7872263B2 (ja) 2020-09-18 2026-06-09 アムジエン・インコーポレーテツド ペプチドマッピング分析のための試料を処理する方法
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
EP4240747A1 (en) 2020-11-05 2023-09-13 Amgen Inc. Materials and methods for protein processing
CN114437212B (zh) * 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
WO2022166739A1 (en) * 2021-02-04 2022-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
US20240190951A1 (en) 2021-04-23 2024-06-13 Amgen Inc. Anti-tslp antibody compositions and uses thereof
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
CA3217029A1 (en) * 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023070948A1 (zh) * 2021-11-01 2023-05-04 江苏荃信生物医药股份有限公司 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的浓缩溶液的制备方法及液体制剂
AU2022388727A1 (en) 2021-11-09 2024-05-16 Amgen Inc. Production of therapeutic proteins
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN114369654B (zh) * 2021-12-21 2023-11-07 广州市妇女儿童医疗中心 川崎病的生物标志物及其应用
CA3244178A1 (en) * 2021-12-24 2023-06-29 Inmagene Pte. Ltd. NEW ANTI-TSLP ANTIBODY
IL315262A (en) * 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
CN118580343B (zh) * 2022-10-21 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
IL323448A (en) * 2023-02-23 2025-12-01 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Monoclonal antibody preparation targeting tslp
JP2026516670A (ja) 2023-04-20 2026-05-26 アムジエン・インコーポレーテツド 相対的な不対グリカン含有量を決定する方法
WO2024238877A1 (en) 2023-05-18 2024-11-21 Medimmune, Llc Treatment of corticosteroid dependent asthma with anti-tslp antibody
CN121311767A (zh) 2023-06-14 2026-01-09 百时美施贵宝公司 糖蛋白的近实时唾液酸定量
EP4731663A2 (en) * 2023-06-22 2026-04-29 Paragon Therapeutics, Inc. Antibodies that bind interleukin 13 and tslp or tslpr and methods of use
CN121443639A (zh) * 2023-06-22 2026-01-30 派拉冈医疗公司 结合tslp和tslpr的抗体及其使用方法
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
AR134101A1 (es) * 2023-10-12 2025-12-03 Innovent Biologics Suzhou Co Ltd Anticuerpos anti-tslp y usos de los mismos
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024385129A1 (en) 2023-11-22 2026-06-11 The United Bio-Technology (Hengqin) Co., Ltd. ANTI-IL-4Rα ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND BISPECIFIC ANTIBODY AND USE THEREOF
CN122295363A (zh) 2023-11-22 2026-06-26 上海华奥泰生物药业股份有限公司 靶向tslp的抗原结合蛋白及应用
IL330343A (en) 2024-01-05 2026-08-01 Medimmune Llc Treatment of chronic obstructive pulmonary disease using an anti-TSLP antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025255028A1 (en) 2024-06-03 2025-12-11 Amgen Inc. High-throughput liquid chromatography-mass spectrometry-based peptide mapping
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2025265071A1 (en) * 2024-06-21 2025-12-26 Paragon Therapeutics, Inc. Antibodies that bind tslp and methods of use
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe
WO2026036112A1 (en) * 2024-08-09 2026-02-12 Paragon Therapeutics, Inc. Compositions and methods comprising combinations of tslp and interleukin 4 receptor alpha antibodies
WO2026067826A1 (zh) * 2024-09-30 2026-04-02 深圳市小分子新药创新中心有限公司 抗tslp单域抗体及其衍生物
WO2026086808A1 (zh) * 2024-10-22 2026-04-30 海南先声药业有限公司 抗tslp抗体及其应用
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content
WO2026136851A1 (en) 2024-12-20 2026-06-25 Amgen Inc. Methods of diethylenetriaminepentaacetic acid (dtpa) quantification

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FI915911A7 (fi) 1989-06-15 1991-12-16 Immunex Corp Interleukiini-7-reseptoreja
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2118119C (en) 1992-04-30 2001-07-31 Robert C. Thompson Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
CA2343979C (en) 1998-09-21 2011-11-15 Schering Corporation Human interleukin-b50, therapeutic uses
CA2349762C (en) * 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
EP1140976A4 (en) 1998-12-30 2003-05-21 Millennium Pharm Inc SECRETED PROTEINS AND THEIR USES
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
EP1282435A2 (en) 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
WO2002000723A2 (en) 2000-06-28 2002-01-03 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
US7964713B2 (en) 2000-06-28 2011-06-21 Amgen Inc. Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
MXPA04007426A (es) * 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
EP1651247B1 (en) 2003-07-18 2008-09-10 Schering Corporation Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
CA2577631A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
WO2006055638A2 (en) * 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
AU2007230868B2 (en) 2006-01-13 2012-02-02 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
TWI449709B (zh) 2014-08-21
JP2021191758A (ja) 2021-12-16
PE20110668A1 (es) 2011-10-01
CA2698382C (en) 2015-07-14
US20110274687A1 (en) 2011-11-10
IL265854A (en) 2019-06-30
EP2205635A1 (en) 2010-07-14
NO2022055I1 (no) 2022-12-09
US7982016B2 (en) 2011-07-19
FR22C1059I1 (fr) 2023-02-03
LUC00289I2 (enExample) 2025-05-12
CY2022036I2 (el) 2023-03-24
HUS2200051I1 (hu) 2022-12-28
CL2008002668A1 (es) 2009-08-14
US20120190829A1 (en) 2012-07-26
DK2205635T3 (en) 2016-07-18
LTPA2022016I1 (enExample) 2023-01-10
CR20150095A (es) 2015-04-06
PE20140232A1 (es) 2014-02-28
AR068508A1 (es) 2009-11-18
SG178781A1 (en) 2012-03-29
PH12017501025B1 (en) 2022-10-26
CY2022036I1 (el) 2023-01-05
EA022796B1 (ru) 2016-03-31
PL2205635T3 (pl) 2016-12-30
JP2024161358A (ja) 2024-11-19
PT2205635T (pt) 2016-07-13
US20160152700A1 (en) 2016-06-02
JP2023065375A (ja) 2023-05-12
CR11319A (es) 2010-04-21
JP5956716B2 (ja) 2016-07-27
US20250154241A1 (en) 2025-05-15
KR20140141666A (ko) 2014-12-10
FR22C1059I2 (fr) 2023-12-22
IL250900A0 (en) 2017-04-30
EA201000471A1 (ru) 2010-10-29
TW201412774A (zh) 2014-04-01
HRP20160638T1 (hr) 2016-07-01
SG10201506251YA (en) 2015-11-27
ZA201001895B (en) 2011-02-23
CY1117702T1 (el) 2017-05-17
JP2015091820A (ja) 2015-05-14
US10287348B2 (en) 2019-05-14
MY150242A (en) 2013-12-31
EP3524622A1 (en) 2019-08-14
AU2008300028B2 (en) 2014-12-18
US8163284B2 (en) 2012-04-24
RS54950B1 (sr) 2016-11-30
HK1145843A1 (zh) 2011-05-06
US20200071393A1 (en) 2020-03-05
EA201590631A1 (ru) 2016-03-31
HUE028361T2 (en) 2016-12-28
NZ583933A (en) 2012-07-27
TW200918554A (en) 2009-05-01
AU2008300028A1 (en) 2009-03-19
CN101809035B (zh) 2014-07-09
LT2205635T (lt) 2016-09-26
KR20100067660A (ko) 2010-06-21
US9284372B2 (en) 2016-03-15
JP2020058365A (ja) 2020-04-16
CN101809035A (zh) 2010-08-18
KR101597371B1 (ko) 2016-02-26
NL301207I2 (nl) 2023-02-02
JP2010538608A (ja) 2010-12-16
CL2012003245A1 (es) 2013-03-22
JP2019038843A (ja) 2019-03-14
CN104231081B (zh) 2022-01-11
WO2009035577A1 (en) 2009-03-19
JO3351B1 (ar) 2019-03-13
ES2581229T3 (es) 2016-09-02
US20090238823A1 (en) 2009-09-24
SI2205635T1 (sl) 2016-09-30
MX2010002590A (es) 2010-03-26
PH12017501025A1 (en) 2018-01-29
JP2017110011A (ja) 2017-06-22
CN104231081A (zh) 2014-12-24
NL301207I1 (nl) 2022-12-21
IL204069A (en) 2017-03-30
EP2205635B1 (en) 2016-05-25
EP2703414A1 (en) 2014-03-05
CA2698382A1 (en) 2009-03-19
JP2026094137A (ja) 2026-06-09

Similar Documents

Publication Publication Date Title
LUC00289I2 (enExample)
BRPI0819773A2 (enExample)
CN300726269S (zh) 墙纸(29a)
CN300729091S (zh) 杯(华夏神龙)
CN300730854S (zh) 蜡烛(45)
CN300729639S (zh) 电子手表(mp4-s808型)
CN300731140S (zh) 手套(15)
CN300730821S (zh) 蜡烛(141)
CN300726987S (zh) 包装盒(双氯芬酸钠)
CN300729590S (zh) 包装袋(哺乳猪配合颗粒饲料)
CN300875662S (zh) 镜柜(18)
CN300729960S (zh) 光电开关用传感器头
CN300726846S (zh) 酒瓶(清样)
CN300727132S (zh) 包装袋(田七纯棉洗衣粉)
CN300729870S (zh) 金属轮毂(537)
CN300726337S (zh) 班椅(oc-18)
CN300747841S (zh) 开关(rk1-010)
CN300728494S (zh) 宠物玩具(猫脸)
CN300875947S (zh) 研磨刀(固定式kcs)
CN300729570S (zh) 包装袋(ⅰ)
CN300728429S (zh) Led投光灯(lve-f480-48rgb\方型)
CN300726938S (zh) 包装盒
CN300728017S (zh) 标识牌(2)
CN300729898S (zh) 电动车轮毂(五星前轮)
CN300729470S (zh) 药品包装盒(硝酸咪康唑搽剂)